
Keywords: ADM; adrenomedullin; ANA; anagrelide; ANASA; patients on anagrelide and aspirin; ASA; aspirin; AV; annexin V; CTR; control group; EC; endothelia cell; EDRF; endothelium derived relaxing factor; EMP; endothelial derived microparticles; ET; essential thromb